Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis on anti-interleukin-1 or-6 therapy

Basit Öğe Kaydı
dc.authoridÖztürk, Kübra/0000-0003-0466-0228
dc.authoridAliyev, Emil/0000-0002-3574-2982
dc.authoridhaşlak, fatih/0000-0002-6963-9668
dc.authoridBarut, Kenan/0000-0001-8459-2872
dc.authoridPaç Kısaarslan, Ayşenur/0000-0002-1800-9922
dc.authoridBAGLAN, ESRA/0000-0001-5637-8553
dc.authoridBağlan, Esra/0000-0001-5637-8553
dc.authorwosidÖztürk, Kübra/ACH-1722-2022
dc.authorwosidAliyev, Emil/JVP-0345-2024
dc.authorwosidhaşlak, fatih/AAN-4799-2020
dc.authorwosidBarut, Kenan/S-5966-2017
dc.authorwosidPaç Kısaarslan, Ayşenur/AEV-4514-2022
dc.authorwosidBAGLAN, ESRA/KOG-0594-2024
dc.authorwosidBağlan, Esra/AGB-8099-2022
dc.contributor.authorUlu, Kadir
dc.contributor.authorAliyev, Emil
dc.contributor.authorKilic Koente, Elif
dc.contributor.authorTanatar, Ayse
dc.contributor.authorTurkmen, Seyma
dc.contributor.authorDogantan, Seyda
dc.contributor.authorKizildag, Zehra
dc.date.accessioned2024-08-04T20:59:55Z
dc.date.available2024-08-04T20:59:55Z
dc.date.issued2024
dc.departmentİnönü Üniversitesien_US
dc.description.abstractObjectives The aim of this study is to investigate the effect of anti-interleukin (IL)-1/-6 biologics on systemic juvenile idiopathic arthritis (sJIA)-associated macrophage activation syndrome (MAS).Methods Demographic, clinical and laboratory data of patients followed up with a diagnosis of sJIA-associated MAS assessed from sixteen paediatric rheumatology centres across the country. The clinical and laboratory features of MAS developing while on biological drugs were compared with those without this treatment.Results One hundred and sixty-two patients were included in the study. Forty-five of the MAS events were detected under the effect of anti-IL-1/-6 biologics, while the patients experiencing the remaining 155 events have not received biological treatment in the last three months. Platelet count [128 (72-232) vs 199 (130-371) 109/l], ferritin level on admission [1107 (676-2050) vs 2863 (1193-9562) ng/ml], C-reactive protein level [15.4 (2.9-56) vs 90 (32-160) mg/l], erythrocyte sedimentation rate [13 (3-36) vs 43.5 (13-77) mm/h] and fever duration [5 (4-7.5) vs 10 (7-14.3) days] were found lower in the group under the impact of anti-IL-1/-6 biologics. Among patients treated with biologics, 26.6% did not meet the published 2016 MAS classification criteria at presentation. The rates of hepatomegaly and splenomegaly were relatively lower in the canakinumab-treated group when compared with those receiving other biologicals or to patients, not on biologicals.Conclusion Anti-IL-1/-6 therapies can mask the clinical and laboratory features of MAS, and proposed guidelines for MAS classification criteria may not be met.en_US
dc.identifier.doi10.1093/rheumatology/keae124
dc.identifier.issn1462-0324
dc.identifier.issn1462-0332
dc.identifier.pmid38441301en_US
dc.identifier.urihttps://doi.org/10.1093/rheumatology/keae124
dc.identifier.urihttps://hdl.handle.net/11616/103636
dc.identifier.wosWOS:001184818400001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherOxford Univ Pressen_US
dc.relation.ispartofRheumatologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectmacrophage activation syndromeen_US
dc.subjectbiological drugsen_US
dc.subjectanakinraen_US
dc.subjectcanakinumaben_US
dc.subjecttocilizumaben_US
dc.subjectanti-interleukin-1en_US
dc.subjectanti-interleukin-6en_US
dc.titleMacrophage activation syndrome in patients with systemic juvenile idiopathic arthritis on anti-interleukin-1 or-6 therapyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu